Skip to main content

Advertisement

SpringerLink
Log in

Expression of TLR9 within human glioblastoma

  • lab. investigation-human/Animal Tissue
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Immunostimulating oligonucleotides containing CpG motifs (CpG-ODN) have shown promising antitumor activity in preclinical glioma models. CpG motifs are specifically recognized by the Toll-like receptor 9 (TLR9), mainly expressed in plasmacytoid dendritic cells (pDCs) and B cells. Expression of TLR9 within human glioma samples has not been investigated. As CpG-ODN is currently under clinical trials in glioma patients, we investigated whether TLR9 is expressed at the RNA levels in a series of 37 human glioblastomas (GBM) by quantitative PCR. TLR9 expression was detected at variable levels, which might suggest that some patients are more likely to benefit from treatment with CpG-ODN than others. No significant relationships between TLR9 expression and age, sex, tumor location, lymphocytes infiltration, oligodendroglial components or survival were found. TLR9 is unlikely to be expressed by tumor cells as no TLR9 expression was detected in pure human GBM xenografts. Immunocytochemistry studies showed TLR9 expression in some macrophages/microglial cells. The expression of TLR9 within human GBM strengthens the rationale for the utilization of CpG-ODN in this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

TLR:

Toll like receptor

GBM:

Glioblastoma

ODN:

Oligodeoxynucleotides

CpG-ODN:

ODN containing a cytosine-guanosine motif

NK:

Natural killer

DC:

Dendritic cell

pDC:

Plasmacytoid DC

References

  1. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY (2003) Primary brain tumours in adults. Lancet 361:323–331

    Article  PubMed  Google Scholar 

  2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  PubMed  CAS  Google Scholar 

  3. Krieg AM (2004) Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep 6:88–95

    Article  PubMed  Google Scholar 

  4. Takeshita F, Leifer CA, Gursel I, Ishii KJ, Takeshita S, Gursel M, Klinman DM (2001) Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol 167:3555–3558

    PubMed  CAS  Google Scholar 

  5. Dalpke AH, Schafer MK, Frey M, Zimmermann S, Tebbe J, Weihe E, Heeg K (2002) Immunostimulatory CpG-DNA activates murine microglia. J Immunol 168:4854–4863

    PubMed  CAS  Google Scholar 

  6. Bowman CC, Rasley A, Tranguch SL, Marriott I (2003) Cultured astrocytes express toll-like receptors for bacterial products. Glia 43:281–291

    Article  PubMed  Google Scholar 

  7. Carpentier AF, Chen L, Maltonti F, Delattre JY (1999) Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 59:5429–5432

    PubMed  CAS  Google Scholar 

  8. Carpentier AF, Xie J, Mokhtari K, Delattre JY (2000) Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res 6:2469–2473

    PubMed  CAS  Google Scholar 

  9. Meng Y, Carpentier AF, Chen L, Boisserie G, Simon JM, Mazeron JJ, Delattre JY (2005) Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int J Cancer 116:992–997

    Article  PubMed  CAS  Google Scholar 

  10. Carpentier A, Laigle-Donadey F, Zohar S, Capelle L, Behin A, Tibi A, Martin-Duverneuil N, Sanson M, Lacomblez L, Taillibert S, Puybasset L, Van Effenterre R, Delattre JY, Carpentier AF (2006) Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro Oncol 8:60–66

    Article  PubMed  CAS  Google Scholar 

  11. Brooks WH, Markesbery WR, Gupta GD, Roszman TL (1978) Relationship of lymphocyte invasion and survival of brain tumor patients. Ann Neurol 4:219–224

    Article  PubMed  CAS  Google Scholar 

  12. Bucciero A, Vizioli L, Giamundo A, Villano M, Quaglietta P, Cerillo A (1990) Prognostic significance of lymphoid infiltration in cerebral malignant gliomas. J Neurosurg Sci 34:145–148

    PubMed  CAS  Google Scholar 

  13. Leuraud P, Taillandier L, Medioni J, Aguirre-Cruz L, Criniere E, Marie Y, Kujas M, Golmard JL, Duprez A, Delattre JY, Sanson M, Poupon MF (2004) Distinct responses of xenografted gliomas to different alkylating agents are related to histology and genetic alterations. Cancer Res 64:4648–4653

    Article  PubMed  CAS  Google Scholar 

  14. Lyons SR, Griffen AL, Leys EJ (2000) Quantitative real-time PCR for Porphyromonas gingivalis and total bacteria. J Clin Microbiol 38:2362–2365

    PubMed  CAS  Google Scholar 

  15. Jack CS, Arbour N, Manusow J, Montgrain V, Blain M, McCrea E, Shapiro A, Antel JP (2005) TLR signaling tailors innate immune responses in human microglia and astrocytes. J Immunol 175:4320–4330

    PubMed  CAS  Google Scholar 

  16. Bsibsi M, Ravid R, Gveric D, van Noort JM (2002) Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 61:1013–1021

    PubMed  CAS  Google Scholar 

  17. Strobl H, Scheinecker C, Riedl E et al (1998) Identification of CD681lin – peripheral blood cells with dendritic precursor characteristics. J Immunol 161:740–748

    PubMed  CAS  Google Scholar 

  18. Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB (2006) The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol 8:261–279

    Article  PubMed  CAS  Google Scholar 

  19. El Andaloussi A, Sonabend AM, Han Y, Lesniak MS (2006) Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia 54:526–535

    Article  PubMed  Google Scholar 

  20. Henault M, Lee LN, Evans GF, Zuckerman SH (2005) The human Burkitt lymphoma cell line Namalwa represents a homogenous cell system characterized by high levels of Toll-like receptor 9 and activation by CpG oligonucleotides. J Immunol Methods 300:93–99

    Article  PubMed  CAS  Google Scholar 

  21. Jego G, Bataille R, Geffroy-Luseau A, Descamps G, Pellat-Deceunynck C (2006) Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 20:1130–1137

    Article  PubMed  CAS  Google Scholar 

  22. Droemann D, Albrecht D, Gerdes J, Ulmer AJ, Branscheid D, Vollmer E, Dalhoff K, Zabel P, Goldmann T (2005) Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res 6:1

    Article  PubMed  Google Scholar 

  23. Watters JJ, Schartner JM, Badie B (2005) Microglia function in brain tumors. J Neurosci Res 81:447–455

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by the Association Oligocyte, the Association pour la Recherche sur les Tumeurs cérébrales (ARTC), the Institut National de la Santé et de la Recherche Médicale (INSERM), the University Pierre & Marie Curie (Paris VI), and the Assistance Publique des Hôpitaux de Paris (AP/HP). Potential conflict of interest: The Assistance Publique-Hopitaux de Paris and Antoine Carpentier hold a patent position on immunotherapy with CpG-ODN.

Author information

Authors and Affiliations

  1. INSERM, U711, Biologie des Interactions Neurones & Glie, Paris, France

    Yuxia Meng, Michèle Kujas, Yannick Marie, Sophie Paris, Joëlle Thillet, Jean-Yves Delattre & Antoine F. Carpentier

  2. Service de Neurologie Mazarin de l’Hôpital Pitié-Salpêtrière, Paris, 75013, France

    Jean-Yves Delattre

  3. Service de Neurologie de l’Hôpital Avicenne, 125 route de Stalingrad, Bobigny, 93009, France

    Antoine F. Carpentier

  4. Assistance Publique des Hôpitaux de Paris, Paris, France

    Michèle Kujas, Jean-Yves Delattre & Antoine F. Carpentier

  5. UFR de Santé, Médecine et Biologie Humaine de Bobigny – Université Paris 13, Paris, France

    Antoine F. Carpentier

Authors
  1. Yuxia Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michèle Kujas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yannick Marie
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sophie Paris
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Joëlle Thillet
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jean-Yves Delattre
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Antoine F. Carpentier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antoine F. Carpentier.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meng, Y., Kujas, M., Marie, Y. et al. Expression of TLR9 within human glioblastoma. J Neurooncol 88, 19–25 (2008). https://doi.org/10.1007/s11060-008-9536-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-008-9536-2

Keywords

Search

Navigation